Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag vs IVIG for Bridging ITP Before Surgery
NCT01621204Phase 3Completed
- Sponsor
- McMaster University
- Start
- Oct 2012
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of eltrombopag in immune thrombocytopenia (ITP) (2 arms), sponsored by McMaster University. Primary endpoint: Achievement of Surgical Platelet Count Threshold Without Rescue. Started Oct 2012; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01621204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621204.